Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer
Status:
Recruiting
Trial end date:
2025-09-15
Target enrollment:
Participant gender:
Summary
This study will enroll patients with HPV-associated oropharyngeal cancer, undergoing
resection of all gross visible disease at the primary site and in the lymph nodes. A total of
36 patients who have had or will require surgery to remove cancer cells prior to starting
chemoradiation may be enrolled. All eligible patients will receive de-intensified
cisplatin-based chemoradiation, with high-risk patients receiving a higher dose and longer
treatment period than other patients on the study. The study will assess whether a
de-intensified version of standard chemoradiation treatment will be just as effective in
treating HPV-associated oropharyngeal cancer while causing less side effects than standard
dosing.